November 2, 2016 / 1:42 PM / a year ago

BRIEF-Oncovent initiates clinical development program for anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer

Nov 2 (Reuters) - Quest Pharmatech Inc :

* Oncovent initiates clinical development program for anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below